Evaluation of oncofertility care in childhood cancer patients: the EU-Horizon 2020 twinning project TREL initiative.
childhood cancer
fertility counseling
late effects
questionnaire
twinning
Journal
Frontiers in pediatrics
ISSN: 2296-2360
Titre abrégé: Front Pediatr
Pays: Switzerland
ID NLM: 101615492
Informations de publication
Date de publication:
2023
2023
Historique:
received:
26
04
2023
accepted:
14
07
2023
medline:
11
8
2023
pubmed:
11
8
2023
entrez:
11
8
2023
Statut:
epublish
Résumé
The 5-year survival rate of childhood cancer exceeds 80%, however, many survivors develop late effects including infertility. The aim of this study was to evaluate the current status of oncofertility care at Vilnius University Hospital Santaros Klinikos (VULSK) within the framework of the EU-Horizon 2020 TREL project. All parents or patients aged 12-17.9 years treated from July 1, 2021 until July 1, 2022 were invited to complete an oncofertility-care-evaluation questionnaire. After completing the questionnaire, patients were triaged to low-risk (LR) or high-risk (HR) of gonadal damage using a risk stratification tool (triage). Data was assessed using descriptive statistics. Questionnaires were completed by 48 parents and 13 children triaged as 36 (59%) LR and 25 (41%) HR patients. Most HR respondents (21/25, 84%) were not counseled by a fertility specialist. Six boys (4 HR, 2 LR) were counseled, none of the girls was counseled. Three HR boys underwent sperm cryopreservation. Only 17 (27.9%, 9 HR, 8 LR) respondents correctly estimated their risk. All counseled boys ( Respondents counseled by a fertility specialist were provided more information on fertility than uncounseled. HR patients were not sufficiently counseled by a fertility specialist. Based on the current experience oncofertility care at VULSK will be improved.
Sections du résumé
Background
UNASSIGNED
The 5-year survival rate of childhood cancer exceeds 80%, however, many survivors develop late effects including infertility. The aim of this study was to evaluate the current status of oncofertility care at Vilnius University Hospital Santaros Klinikos (VULSK) within the framework of the EU-Horizon 2020 TREL project.
Methods
UNASSIGNED
All parents or patients aged 12-17.9 years treated from July 1, 2021 until July 1, 2022 were invited to complete an oncofertility-care-evaluation questionnaire. After completing the questionnaire, patients were triaged to low-risk (LR) or high-risk (HR) of gonadal damage using a risk stratification tool (triage). Data was assessed using descriptive statistics.
Results
UNASSIGNED
Questionnaires were completed by 48 parents and 13 children triaged as 36 (59%) LR and 25 (41%) HR patients. Most HR respondents (21/25, 84%) were not counseled by a fertility specialist. Six boys (4 HR, 2 LR) were counseled, none of the girls was counseled. Three HR boys underwent sperm cryopreservation. Only 17 (27.9%, 9 HR, 8 LR) respondents correctly estimated their risk. All counseled boys (
Conclusions
UNASSIGNED
Respondents counseled by a fertility specialist were provided more information on fertility than uncounseled. HR patients were not sufficiently counseled by a fertility specialist. Based on the current experience oncofertility care at VULSK will be improved.
Identifiants
pubmed: 37565239
doi: 10.3389/fped.2023.1212711
pmc: PMC10411952
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1212711Informations de copyright
© 2023 Stukaite-Ruibiene, van der Perk, Vaitkeviciene, Bos, Bumbuliene, van den Heuvel-Eibrink and Rascon.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Fertil Steril. 2013 May;99(6):1514-22
pubmed: 23541406
BMC Med. 2016 Jan 04;14:1
pubmed: 26728489
Support Care Cancer. 2002 Nov;10(8):579-600
pubmed: 12436217
Health Care Women Int. 2015;36(10):1143-59
pubmed: 25562531
BMC Cancer. 2022 Apr 25;22(1):450
pubmed: 35468746
Cancer. 2012 Mar 15;118(6):1710-7
pubmed: 21887678
Hum Reprod. 2010 Oct;25(10):2516-26
pubmed: 20719811
Cancer. 2015 Nov 15;121(22):3938-47
pubmed: 26264701
Patient Educ Couns. 1998 Oct;35(2):83-8
pubmed: 10026551
Med Decis Making. 2003 Jul-Aug;23(4):281-92
pubmed: 12926578
Arch Dis Child. 2004 Aug;89(8):736-7
pubmed: 15269072
Lancet Diabetes Endocrinol. 2015 Jul;3(7):556-67
pubmed: 25873571
Lancet Oncol. 2021 Feb;22(2):e45-e56
pubmed: 33539753
Acta Obstet Gynecol Scand. 2019 May;98(5):545-549
pubmed: 30723908
Lancet Oncol. 2014 Jan;15(1):35-47
pubmed: 24314616
Reprod Sci. 2017 Aug;24(8):1111-1120
pubmed: 28701069
Pediatr Hematol Oncol. 2009 Jun;26(4):252-60
pubmed: 19437327
Pediatr Blood Cancer. 2014 Nov;61(11):2054-8
pubmed: 25065353
J R Soc Med. 2003 May;96(5):219-22
pubmed: 12724430
Lancet Oncol. 2021 Feb;22(2):e57-e67
pubmed: 33539754
Lancet. 2017 Dec 9;390(10112):2569-2582
pubmed: 28890157
Ann Oncol. 2013 Oct;24 Suppl 6:vi160-70
pubmed: 23813932
PLoS One. 2021 Mar 5;16(3):e0246344
pubmed: 33667234
Fertil Steril. 2017 Sep;108(3):407-415.e11
pubmed: 28739117
BMC Cancer. 2012 Aug 23;12:363
pubmed: 22917040
J Clin Oncol. 2018 Jul 20;36(21):2169-2180
pubmed: 29874135
CA Cancer J Clin. 2014 Mar-Apr;64(2):83-103
pubmed: 24488779
Hum Reprod. 2017 Nov 1;32(11):2250-2253
pubmed: 29040512
Pediatr Blood Cancer. 2014 Jan;61(1):53-67
pubmed: 23940101
Med Decis Making. 1995 Jan-Mar;15(1):25-30
pubmed: 7898294
Ginekol Pol. 2021;92(4):262-270
pubmed: 33757149
Lancet Oncol. 2017 Jun;18(6):719-731
pubmed: 28410997
Ann Pediatr Endocrinol Metab. 2013 Dec;18(4):168-72
pubmed: 24904872
J Assist Reprod Genet. 2011 Mar;28(3):269-77
pubmed: 21110080
Fertil Steril. 2019 Dec;112(6):1022-1033
pubmed: 31843073
Psychooncology. 2008 May;17(5):506-11
pubmed: 17935145
J Clin Oncol. 2016 Sep 20;34(27):3240-7
pubmed: 27382091
Lancet Oncol. 2017 Feb;18(2):e75-e90
pubmed: 28214419
J Clin Oncol. 2013 Jul 1;31(19):2500-10
pubmed: 23715580
Lancet Oncol. 2021 Feb;22(2):e68-e80
pubmed: 33539755